Spain Opens First Biosafety Level 4 Laboratory, Elevating Global Health Security

Madrid, Spain – In a landmark achievement for global health security, Spain has inaugurated its first Biosafety Level 4 (BSL-4) laboratory, located at the GSK’s Health Global R&D Center in Tres Cantos, Madrid.¹ This facility represents the highest level of biological containment, designed to safely study dangerous pathogens for which there are currently no treatments or vaccines.

A New Era for Infectious Disease Research

The new BSL-4 laboratory, a €5.2 million investment by GSK, is the first of its kind operated by a pharmaceutical company globally, and one of only a few such facilities in Europe.^{1, 4} It will focus on researching severe infectious diseases, including multidrug-resistant tuberculosis and Crimean-Congo hemorrhagic fever.¹ The facility’s opening marks a significant step in proactively addressing potential pandemic threats and developing innovative solutions for vulnerable populations.

What is a BSL-4 Laboratory?

BSL-4 laboratories are designed for work with the most dangerous pathogens, including viruses like Ebola and Marburg.² These labs employ stringent safety protocols to prevent the accidental release of these agents into the environment. Currently, there are 51 BSL-4 labs in 27 countries worldwide, with eight located within the European Union.²

Inside the GSK BSL-4 Facility

The GSK laboratory will be staffed by a team of seven researchers, five of whom are women.² Researchers entering the BSL-4 suite undergo a rigorous protocol, including complete disrobing, showering, and donning a hermetically sealed, positive-pressure suit.² Entry is always conducted in pairs, with mutual evaluation before entering the containment area. Due to the stringent safety requirements, researchers can only remain inside for a maximum of four hours at a time, and are prohibited from eating, drinking, or using restroom facilities during their shift.²

Research Focus: Tackling Global Health Challenges

The initial research priorities for the GSK BSL-4 laboratory include:

• Multidrug-resistant tuberculosis: Addressing a growing global health crisis where approximately half a million people annually lack effective treatment options.¹
• Crimean-Congo hemorrhagic fever: Investigating a tick-borne disease endemic in the Balkans with significant pandemic potential.¹

Collaboration and Future Outlook

The Spanish government is also constructing its own BSL-4 laboratory at the Instituto Carlos III in Majadahonda, expected to be operational next year.² GSK has established a collaborative agreement with the government, and President Pedro Sánchez visited the GSK facility on March 3, 2026.² This collaboration will position Spain at the forefront of research into pandemic-potential diseases.

David Barros, Director of I+D in Salud Global at GSK, emphasized the importance of the new facility, stating, “With this installation, we are taking a decisive step towards finding new solutions to diseases that disproportionately affect the most vulnerable populations and driving new treatments to improve global health.”¹

The opening of Spain’s first BSL-4 laboratory signifies a crucial investment in global health security and underscores the importance of proactive research in the face of emerging infectious disease threats.

Sources:

1. GSK: Así es el primer laboratorio de investigación de máxima bioseguridad (BSL-4) en España
2. El País: Dentro del primer laboratorio en España de alta bioseguridad
3. El Economista: GSK sitúa a España en la élite de la bioseguridad
4. El Mundo: Primer laboratorio de bioseguridad nivel 4 en España